Get started

Tilray

TILRAY - Tecnical AnalysisDear Traders, After TILRAY's crazy 92% run, it was time for it to retrace, and it did. Now that TILRAY has found support at the 0.382 fib level, we need to think. There are 2 possibilities here, or we retrace down to the 200 ema (which would be logic), or we have found enough support at this fib level to start building up again. I drew a green line marking a resistance line, and TLRY needs to breakout of it before turning bullish again. A good entry would be the 200 ema on the 1hr chart. What are your thoughts ?
NASDAQ:TLRY
by Raw_Blitz
TILRAY - Technical AnalysisDear Traders, We can see that TLRY has broken out but without big volume (which I expect, to be honest). I think most Traders/Bots are waiting for the MACD to cross upwards signal before creating another run-up. Let's see how this plays out. If you enter, don't forget your stop loss. About TILRAY: Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. Its products include dried cannabis and cannabis extracts. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada. Latest news: www.fool.com
NASDAQ:TLRYLong
by Raw_Blitz
TLRY - Pump, Dump, RepeatTilray's recent bubble pop has a lot of shareholders in panic mode. Despite the massive spread and a 60% drop from the high in just two days, an incredible amount of speculation still remains in the cannabis sector. What makes TLRY different than other cannabis stocks is the incredibly low float of ~18M shares, which serves to amplify the effects of speculative trading (in both directions). Compare the float to the average daily volume of 9M shares, and you will see what I mean. TLRY touched the 38.2% fib level after market Friday, and according to the 5/26 MACD has some room left to drop. I set my fibonacci bounds to the high near $300, and low at listing price around $20. It is difficult to tell how far down something this volatile will go, but according to the setup we can expect a bounce around the $60-$80 price range (likewise, when the 26-EMA touches $100, a previous support/resistance level). There will likely be a mini-bounce around $100 but I do not count on it sticking. 5/26 MACD indicates we have at least a few days before this thing will start to find a bottom. Implied volatility will be crushed as standard deviation reduces from the averaging of pump and dump outliers, which will in turn lower option premiums. Planning to buy some covered calls if the setup bites, otherwise reassessment will be necessary. Worst case scenario for this setup is that it hits the $60-$80 range and flattens, crushing option premium even further (which can be mitigated through use of covered calls combined with put credit spreads if necessary). Recreational legalization in Canada on Oct. 17th along with TLRY being the first Canadian cannabis company to obtain operational license within the U.S. add fuel to the fire that is speculation. Also of note is the disruptive impact that cannabis companies will have on traditional pharmaceuticals, a market holding ~$1.1T capitalization. There is also the potential for more states to legalize cannabis for either recreational/medical use. These all fuel speculative interactions within the market. A note on long term TLRY trades: there are 10M+ shares in lockup until January 2019, which will become public sometime then. I do not suggest holding any positions into January as the market will likely react violently to the increase in float.
NASDAQ:TLRYLong
by Derivati_Capital
5
Short on CRON - Divergence Technicals - CRON 9.78% broke out of a strong resistance today but failed to hold. Price is back within the parallel channel . In addition, RSI is diverging from price action. These are really simple, but strong bearish signals. Fundamentals - Following the success of Tilray 38.12% , CRON 9.78% soared two days in a row, breaking new highs. However, no significant fundamental news within the company justifies such a jump in prices. I believe that the 560% change in price in 52 weeks is clearly an overreaction and could lead to a massive dump. Institutional investors are massively short on Cannabis stocks in general; CRON 9.78% is overpriced and will drop back down to the $9.13-10 level.
NASDAQ:CRONShort
by Tutur
5
Tilray most likely to hit ~$174aicody.com Company Summary Tilray, Inc. (NASDAQ: TLRY) is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients in ten countries spanning five continents. Tilray has reported financial results for second quarter of 2018 and six months ended June 30, 2018. “We are very pleased with our strong start to 2018. Tilray is well-positioned to continue to pioneer the development of the global medical cannabis market and to become a leader in the adult-use cannabis market in Canada,” said Mr. Brendan Kennedy, President and Chief Executive Officer of Tilray. “In the second quarter, we generated significant revenue growth as a result of our global strategy, our multinational distribution network and our commitment to research, innovation, quality and operational excellence. Second Quarter 2018 Financial Highlights Revenue increased to $9.7 (C$12.7) million, up 95.2% compared to the second quarter of last year. The increase in revenue was driven by increased patient demand in Canada, sales to other Licensed Producers and international sales. Total kilogram equivalents sold increased 745 kilograms to 1,514 kilograms, or 97%, compared to the prior year. Average net selling price per gram increased from $6.20 to $6.38 (C$8.12 to C$8.36) for the three months ended June 30, 2017 and 2018, respectively. The increase was primarily due to growth in higher potency product and extract sales, partially offset by an increase in wholesale revenues. Net loss for the quarter was $12.8 million compared to $2.4 million for the second quarter of 2017. Net loss includes non-cash stock compensation charges of $5.6 million compared to a $35 thousand charged in the prior year period. Adjusted EBITDA was a loss of $4.7 million compared to a loss of $1.9 million the second quarter last year. The increased net loss and Adjusted EBITDA decline was primarily due to the increase in operating expenses related to continued growth, expansion of international teams, and costs related to financing and the initial public offering (“IPO”). Business Highlights in 2018 to date: Successfully completed IPO in July whereby 10.350 million shares of Class 2 Common Stock were sold at an initial price to the public of $17.00 per share. The Company received net proceeds of $163.6 (C$216.9) million after the underwriting discount. Net proceeds will be used to fund the build out of cultivation and processing capacity, repay outstanding principal and interest under the Privateer Holdings debt facilities, and for future acquisitions and working capital. Prior to the IPO, completed Series A funding of $55.0 (C$69.2) million from leading institutional investors. Signed agreements to supply cannabis to adult-use consumers in seven Canadian provinces and territories (British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, the Yukon territory and the Northwest Territories). Entered into a strategic agreement with Sandoz Canada, a division of Novartis, to collaborate on the creation and sale of co-branded and co-developed non-combustible medical cannabis products. Signed agreement with Shoppers Drug Mart Inc., Canada’s largest pharmacy chain with more than 1,200 pharmacies and expect to supply Tilray products following approval of Shoppers’ application to become a Licensed Producer. Signed binding letter of intent with Pharmasave, one of Canada’s leading independent pharmacy chains with more than 650 pharmacies, which Tilray anticipates will allow it to supply Pharmasave stores with Tilray products contingent upon a change in laws that permits Canadian pharmacies to distribute medical cannabis to patients. Completed exports to Argentina, South Africa and the United Kingdom, making Tilray products available in 11 countries on five continents. Launched High Park Holdings Ltd., Tilray’s wholly owned subsidiary formed to serve the pending adult-use market in Canada with a broad-based portfolio of cannabis brands and products. Announced the launch of the CANACA™ brand, a new cannabis brand celebrating Canadian roots, values and this historical moment in Canada as the country becomes the world’s first G7 nation to federally legalize cannabis through adult-use legalization. Announced clinical study results of Tilray® 2:100 product showed promise in Canada’s first pediatric study of mixed THC/CBD medical cannabis oil for children with drug-resistant epilepsy. Statistics Shares Outstanding: 76.5M Avg Daily Vol: 8.5M Market Cap: 14.08B 52-Week High: $151.18 52-Week Low: $20.10 Forward PE: NA Annual Div/Dividend Yield: $0.00 / 0.00% Annual Rev: 23.1M Inst Own: 0.0% 1-Month Return: NA 3-Month Return: NA Next Earnings Report Date: 08/29/2018 Earnings ESP: -0.18 Revenue Per Employee: $85,912 Money Flow Ratio: 1.08% Profitability Revenue Growth: 62.5% (Sector Average 3.3%) Gross Margin: 53.0% (Sector Average 62.4%) Return on Equity: NA (Sector Average -19.2%) Net Margin: -52.9% (Sector Average -10.4%) Debt Current Ratio: 1.1 (Sector Average 2.9) Debt-to-Capital: 230.5% (Sector Average 25.8%) Interest Funding: -12.5% (Sector Average 0.3%) Interest Coverage: -11.6 (Sector Average -4.7) Dividend Dividend Growth: NA (Sector Average 5.5%) Dividend Payout: NA (Sector Average 66.7%) Dividend Coverage: NA (Sector Average 2.1) Dividend Yield: NA (Sector Average 0.00%) Top Peer Companies Akcea Therapeutics Inc (AKCA) Akorn Inc (AKRX) American Cannabis Company Inc (OTCMKTS: AMMJ) Amphastar Pharmaceuticals Inc (AMPH) Aphira Inc (TSE: APH) Aurora Cannabis Inc (TSE: ACB) Cambrex Corp (CBM) CannaRoyalty Corp (CNSX: CRZ) Canopy Growth Corp (CGC) Corcept Therapeutics Inc (CORT) Cronos Group Inc (CRON) Emergent BioSolutions Inc (EBS) Hydropothecary Corp (TSE: HEXO) Innoviva Inc (INVA) Maricann Group Inc (CNSX: MARI) Medmen Enterprises Inc (CNSX: MMEN) MedReleaf Corp (MEDFF) OPKO Health Inc (OPK) Pacira Pharmaceuticals Inc (PCRX) Theravance Biopharma Inc (TBPH) VIVO Cannabis Inc (ABCCF) 12 Month Price Target Mean: USD$115.05 High: USD$174.33 Low: USD$90.32 Revenue Growth Revenue increased to $9.7 (C$12.7) million, up 95.2% compared to the second quarter of last year. The increase in revenue was driven by increased patient demand in Canada, sales to other Licensed Producers and international sales. Earnings Surprise Positive (+18.4%)
NASDAQ:TLRYLong
by aicody
2